Prednisolone Treatment Does Not Interfere with 2'-O-Methyl Phosphorothioate Antisense-Mediated Exon Skipping in Duchenne Muscular Dystrophy

Ingrid E.C. Verhaart,¹ Hans Heemskerk,¹ Tatyana G. Karnaoukh,² Ingrid G.M. Kolfschoten,² Anne Vroon,² Gert-Jan B. van Ommen,¹ Judith C.T. van Deutekom,² and Annemieke Aartsma-Rus¹

Abstract

In Duchenne muscular dystrophy (DMD), dystrophin deficiency leading to progressive muscular degeneration is caused by frame-shifting mutations in the *DMD* gene. Antisense oligonucleotides (AONs) aim to restore the reading frame by skipping of a specific exon(s), thereby allowing the production of a shorter, but semifunctional protein, as is found in the mostly more mildly affected patients with Becker muscular dystrophy. AONs are currently being investigated in phase 3 placebo-controlled clinical trials. Most of the participating patients are treated symptomatically with corticosteroids (mainly predniso[lo]ne) to stabilize the muscle fibers, which might affect the uptake and/or efficiency of AONs. Therefore the effect of prednisolone on 2'-O-methyl phosphorothioate AON efficacy in patient-derived cultured muscle cells and the *mdx* mouse model (after local and systemic AON treatment) was assessed in this study. Both *in vitro* and *in vivo* skip efficiency and biomarker expression were comparable between saline- and prednisolone-cotreated cells and mice. After systemic exon 23-specific AON (23AON) treatment for 8 weeks, dystrophin was detectable in all treated mice. Western blot analyses indicated slightly higher dystrophin levels in prednisolone-treated mice, which might be explained by better muscle condition and consequently more target dystrophin pre-mRNA. In addition, fibrotic and regeneration biomarkers were normalized to some extent in prednisolone- and/or 23AON-treated mice. Overall these results show that the use of prednisone forms no barrier to participation in clinical trials with AONs.

Introduction

DUCHENNE MUSCULAR DYSTROPHY (DMD) is a severe, muscle-wasting disease, affecting about 1 in 3500 newborn boys. First symptoms generally become visible before the age of 5 years, followed by wheelchair dependency at about the age of 10 years. Most patients die at about 30 years of age, predominantly due to heart and respiratory failure (Emery, 2002).

DMD is caused by mutations in the *DMD* gene, located on the short arm of the X chromosome (Xp21), leading to the complete loss of the dystrophin protein it encodes (Hoffman *et al.*, 1987; Koenig *et al.*, 1988). Dystrophin stabilizes muscle fibers by connecting intracellular actin to the extracellular matrix (Blake *et al.*, 2002), through a long repeat domain that intersperses the two essential binding domains. In the absence of dystrophin, muscle fibers will be continuously damaged during contraction, which leads to an influx of

inflammatory cells and secretion of cytokines, in particular tumor necrosis factor (TNF)- α (Spencer and Tidball, 2001; Porter *et al.*, 2002; Tidball, 2005). TNF- α activates the I κ B kinase (IKK)/NF- κ B signaling pathway in macrophages, which in turn increases necrosis and inflammation and reduces regeneration in muscle fibers (Hayden and Ghosh, 2004; Acharyya *et al.*, 2007). Fibrotic tissue is formed by fibroblasts and even by satellite cells, which, once fibrotic tissue has been formed, start to produce collagen type I and no longer take part in regeneration (Alexakis *et al.*, 2007). Fibroblasts from dystrophin-negative *mdx* mice, a naturally occurring mouse model for DMD (Sicinski *et al.*, 1989), remain activated even when activating factors from immune cells have dissipated (Mezzano *et al.*, 2007). These processes further increase fibrosis, which gradually replaces the damaged muscle fibers. Especially fibrosis in the endomysium is negatively correlated with functional performance in patients (Desguerre *et al.*, 2009). Last, muscle regeneration is

¹Department of Human Genetics, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.

²Prosensa Therapeutics, 2333 CH Leiden, The Netherlands.

reduced through induction of the transforming growth factor (TGF)- β pathway by the fibrotic tissue (Chen *et al.*, 2005).

At present there is no cure for DMD. However, there are pharmacological approaches that try to combat the symptoms caused by the underlying genetic defect. The main treatment is the use of the corticosteroids prednisone, prednisolone (the active form of prednisone), or deflazacort (an oxazolidine derivative of prednisone) (Khan, 1993). Their exact mechanism of action is unknown, but studies have shown that corticosteroid-treated patients have increased muscle strength and remain ambulant for about 3 years longer than untreated patients (Merlini *et al.*, 2003; Angelini, 2007). In *mdx* mice a positive effect of prednisolone on muscle strength and histology (decrease in centrally located nuclei) was seen (Baltgalvis *et al.*, 2009). This beneficial effect is probably through the antiinflammatory effects and the reduction of muscle necrosis (Gaud *et al.*, 2004; Angelini, 2007). In a dystrophin-deficient *Caenorhabditis elegans*, the amount of degenerating cells is decreased after treatment with prednisone (Gaud *et al.*, 2004). Because *C. elegans* has only a simple immune system, this indicates that other mechanisms are involved as well. One study suggests that deflazacort activates the calcineurin/NF-AT (nuclear factor of activated T cell) pathway and thereby increases the expression of NF-AT target genes, among which is the dystrophin homolog utrophin, which can partly take over the function of dystrophin, thereby decreasing the dystrophic muscle fiber pathology (St-Pierre *et al.*, 2004). An alternative possibility is that the anabolic effect of corticosteroids in patients increases muscle regeneration and growth by enhancing proliferation of myogenic precursor stem cells or myoblasts (Angelini, 2007). Furthermore, corticosteroids have a positive effect on calcium homeostasis, which is deregulated in patients with DMD (Khan, 1993). Unfortunately, corticosteroids also have deleterious side effects (Fisher *et al.*, 2005) such as osteoporosis (Lo Cascio *et al.*, 1995), weight gain, growth inhibition (Merlini *et al.*, 2003), delayed puberty, and cataracts (Jobling and Augusteyn, 2002). They have a catabolic effect on muscle in unaffected individuals (Schakman *et al.*, 2009), but in DMD this is generally abrogated by the positive effects. In *mdx* mice it has even been shown that prednisolone induced fibrosis in the heart (Bauer *et al.*, 2009), but this is not observed in patients with DMD, in whom corticosteroid use prevents/delays ventricular dysfunction (Silversides *et al.*, 2003; Markham *et al.*, 2008).

Approaches aiming to restore the underlying genetic defect of DMD are currently under investigation. At the moment, the most promising strategy is exon skipping, using antisense oligonucleotides (AONs) to restore the disrupted reading frame. These AONs target a specific region in the pre-mRNA involved in appropriate exon inclusion. In this way they prevent the exon from being recognized by the spliceosome and, consequently, it will not be incorporated in the mRNA (Aartsma-Rus *et al.*, 2009). The resulting in-frame mRNA transcript allows translation of a protein that is internally deleted, but contains the essential actin and extracellular matrix binding domains, and therefore it will be partially to largely functional (Aartsma-Rus and van Ommen, 2007). These dystrophins will resemble the internally deleted proteins found in patients with Becker muscular dystrophy (BMD), who have a much milder phenotype and longer life expectancy (Monaco *et al.*, 1988; Koenig *et al.*,

1989). Proof of principle has been obtained *in vitro* with both healthy and patient-derived cultured primary human myoblasts (Aartsma-Rus *et al.*, 2002, 2003, 2004) and in *in vivo* studies in *mdx* mice (Wu *et al.*, 2008; Heemskerk *et al.*, 2009; Yin *et al.*, 2009; Goyenvalle *et al.*, 2010). Exon skipping can be performed using AONs with various backbone chemistries (Heemskerk *et al.*, 2009). For *in vivo* studies, mainly 2'-O-methyl phosphorothioate (2OMePS) and phosphorodiamidate morpholino oligomer (PMO) AONs are used. These have also been used in two exploratory clinical trials with local injections, which have shown positive results (van Deutekom *et al.*, 2007; Kinali *et al.*, 2009). A phase 1–2a systemic clinical trial with 2OMePS AONs has been completed and a dose-dependent effect was seen after subcutaneous injections of AONs against exon 51. Treatment resulted in exon skipping and dystrophin expression at up to ~15% of normal expression levels. In an open label extension study, 3 months of weekly injections with the highest dose resulted in an increase in functional performance, without serious adverse events (Goemans *et al.*, 2011). The first systemic clinical trial with PMOs showed promising results as well: 7 of 19 patients, mainly in the higher dose groups, showed dystrophin restoration after treatment, albeit with considerable variability between patients (Cirak *et al.*, 2011).

Larger multicenter placebo-controlled trials with 2OMePS AONs have now been initiated. The majority of the patients involved in these trials will use corticosteroids, primarily prednisolone. Thus far the effect of corticosteroid treatment on AON biodistribution and skipping efficiency has not been studied. Corticosteroids are thought to stabilize the damaged muscle fiber membrane, whereas the exon-skipping approach actually makes use of the fact that in patients with DMD the membrane is leaky, allowing higher uptake of AONs (Heemskerk *et al.*, 2010). Thus, corticosteroid treatment could result in decreased uptake of AONs and lower levels of exon skipping and dystrophin restoration. On the other hand, the exon-skipping approach requires a sufficient amount of pre-mRNA to be effective, which is expressed only by muscle tissue and not by fibrotic tissue. Therefore, more dystrophin pre-mRNA might be available when the muscle is better preserved, due to corticosteroid treatment. To elucidate this, the effect of cotreatment with 2OMePS AONs and prednisolone on patient-derived muscle cell cultures and in dystrophic *mdx* mice was assessed.

The results suggest that prednisolone treatment does not interfere with 2OMePS AON uptake and exon-skipping levels in patient-derived muscle cells *in vitro* and in *mdx* mice *in vivo*. Prednisolone might even enhance the dystrophin expression induced by exon 23-specific AONs (23AONs) in *mdx* mice.

Materials and Methods

Cell cultures and AON transfection

Two patient cell cultures, DL589.2 (deletion exon 51–55) and 53914.1 (deletion exon 52) (previously described by Aartsma-Rus *et al.*, 2003, 2004) were grown to 80% confluency on high-serum medium. Differentiation was induced by switching to low-serum medium. Prednisolone in saline (Leiden University Medical Center [LUMC] Pharmacy, Leiden, The Netherlands) was added in doses ranging from 0.2 to 2.25 μ g/ml to determine optimal concentration. For

AON transfection experiments prednisolone was added at 0.75 $\mu\text{g}/\text{ml}$ to the medium. When differentiation was deemed sufficient (generally after approximately 10 days), h50AON1 and PRO051 (Aartsma-Rus *et al.*, 2002) were transfected in the respective patient cell cultures and the control cells, using polyethylenimine (Exgen 500; MBI Fermentas, Sankt Leon-Rot, Germany), according to the manufacturer's instructions and using 2.5 μl of PEI per microgram of AON ($n=12$ per condition per cell line). All AONs were 2'-O-methyl RNA oligonucleotides with a full-length phosphorothioate backbone (Eurogentec [Seraing, Belgium] and Prosensa Therapeutics [Leiden, The Netherlands]). Cells were harvested 2 days after transfection.

In vivo 23AON and prednisolone treatment

All experiments were approved by the local animal ethics experimental committees. Mice were housed in individually ventilated cages in the animal facility of the LUMC or Laboratory of Pharmacology and Toxicology (LPT, Hamburg, Germany) and received food and drink *ad libitum*. Intramuscular experiments were performed at the LUMC and *mdx* mice (C57Bl/10ScSn-DMD^{mdx}/J) with one or two copies of the utrophin gene (*mdx/utrn*^{+/-} or *mdx/utrn*^{+/+}) were obtained from our own breeding facilities. The systemic experiments were performed at the LPT and *mdx* mice from Charles River Laboratories (Sulzfeld, Germany) were used.

For the intramuscular 23AON treatment, mice were subcutaneously (Payne *et al.*, 2006) injected with prednisolone (1 mg/kg; LUMC Pharmacy) ($n=4$) or saline ($n=4$) on weekdays from the age of 4 weeks until the end of the experiment. At the age of 8 weeks, the mice were anesthetized with isoflurane and intramuscularly injected via both gastrocnemius muscles on two consecutive days with 2.9 nmol ($\sim 20 \mu\text{g}$) of M23D(+2-18), 2'-O-methyl phosphorothioate RNA oligonucleotides with a full-length phosphorothioate backbone, specifically targeting exon 23 (Mann *et al.*, 2002) (produced by Prosensa Therapeutics), in 40 μl of saline. Ten days after the second injection the mice were killed by cervical dislocation and muscles were isolated.

For the systemic 23AON treatment male *mdx* mice ($n=8-10$ per group) at the age of 5 weeks (day 1) were anesthetized with ether and underwent surgery to implant a prednisolone pellet (1 mg/kg/day in a 60-day slow-release subcutaneous pellet; Gueron *et al.*, 2010) under the dorsal skin (groups 2 and 4) or underwent mock surgery (groups 1 and 3) at the start of the experiment. Mice were injected subcutaneously with 250 mg of M23D(+2-18)/kg body weight once daily for 5 days in test week 1 and 100 mg of M23D(+2-18)/kg body weight twice per week in test weeks 2 to 8 (groups 3 and 4), or saline (groups 1 and 2). Mice were killed 10 days after the last injections and muscles (gastrocnemius, tibialis anterior, quadriceps, heart, and diaphragm) and organs (liver and kidney) were isolated, snap frozen in liquid nitrogen-cooled 2-methylbutane, and stored at -80°C .

Measurement of creatine kinase levels

Blood samples were taken weekly via the tail vein. Samples were centrifuged at $1700\times g$ for 10 min at 4°C . Serum was stored at 4°C and creatine kinase (CK) levels were measured after diluting the samples 10 times in Dulbecco's phosphate-buffered saline (D-PBS; Invitrogen, Carlsbad, CA)

and were measured with a Reflotron system (Roche Diagnostics, Basel, Switzerland) with CK-strips (Roche).

RNA extraction and analysis of exon skipping by RT-PCR

Harvested cells were lysed with RNA-Bee (Campro Scientific, Veenendaal, The Netherlands). Total RNA was extracted and 400 ng of RNA was used for RT-PCR analysis, using Transcriptor reverse transcriptase polymerase (Roche) in 20 μl at 55°C for 30 min with an appropriate primer (primer sequences on request). cDNA was amplified by nested PCR. Three microliters of cDNA was amplified in a 25- μl reaction for 20 cycles of 94°C (40 sec), 60°C (40 sec), and 72°C (80 sec), followed by 32 cycles of 94°C (40 sec), 60°C (40 sec), and 72°C (60 sec), with 1.5 μl of PCR product in a 50- μl reaction.

Muscles were minced in TriPure isolation reagent (Roche), using MagNA Lyser green beads (Roche) or zirconium beads (1.4 mm; OPS Diagnostics, Lebanon, NJ) according to the manufacturer's instructions. Total RNA was extracted and 1 μg of RNA was used for RT-PCR analysis, using Transcriptor reverse transcriptase polymerase (Roche) in 20 μl at 42°C for 45 min with random hexamer primers (20 ng/ μl). Then, 1.5 μl of cDNA was amplified in a 50- μl reaction for 30 cycles of 94°C (30 sec), 60°C (30 sec), and 72°C (30 sec), as previously described (Spitali *et al.*, 2010). All PCR products were visualized on 1.5 or 2% agarose gels and quantified with an Agilent 2100 bioanalyzer (Agilent Technologies, Palo Alto, CA). PCR products were quantified using a DNA 1000 LabChip on the Agilent 2100 bioanalyzer (Agilent Technologies) according to the manufacturer's protocol. Bioanalyzer analysis has been shown to be an accurate method for exon-skipping quantification in *mdx* muscle (Spitali *et al.*, 2010).

Hybridization-ligation assay

The assay for measuring the concentration of 23AON in tissue samples is based on a previously published hybridization-ligation assay (Yu *et al.*, 2002). Briefly, a signal probe (containing a peptide for antibody recognition) and a template (complementary to 23AON and the probe) were added to homogenized tissue samples. This was followed by a ligation step that takes place only when both AON and probe are bound to the template. Unbound probe was then washed away and the amount of probe-AON was detected with enzyme-linked antibodies against the probe. Muscles/organs were homogenized in proteinase K buffer (0.1 M Tris-HCl [pH 8.5], 0.2 M NaCl, 0.2% sodium dodecyl sulfate [SDS], and 5 mM EDTA) containing proteinase K (2 mg/ml; Invitrogen), using MagNA Lyser green beads (Roche) or zirconium beads (1.4 mm; OPS Diagnostics), by grinding in a MagNA Lyser (Roche) followed by incubation overnight at 55°C with gentle agitation. Calibration curves of the analyzed 23AON prepared in 60 times pooled control mouse *mdx* tissue in PBS were included. All tissues were diluted in pooled control *mdx* mouse tissue. The muscle samples were diluted 500 and 1000 times, and liver and kidney tissue 1000 and 5000 times. All analyses were performed in duplicate.

Protein extraction and Western blot analysis

Western blotting was performed as described (Anderson and Davison, 1999; Aartsma-Rus *et al.*, 2003; Heemsker

et al., 2009). Briefly, muscles were homogenized in 75 mM Tris-HCl (pH 6.8)–15% SDS, using MagNA Lyser green beads (Roche), by grinding in a MagNA Lyser (Roche). Protein concentrations were determined with a Pierce bicinchoninic acid (BCA) protein assay kit (Thermo Fisher Scientific, Waltham, MA) according to the manufacturer's instructions. Samples containing 75 μ g of protein were made in 75 mM Tris-HCl (pH 6.8), 15% SDS, 5% 2-mercaptoethanol, 2% glycerol, and 0.001% bromophenol blue, boiled for 5 min, loaded on a 4–7% gradient polyacrylamide gel, and run overnight at 4°C. Control samples containing 3.75 (5%), 1.5 (2%), 0.75 (1%), and 0.075 (0.1%) μ g of protein were used as a reference. Gels were blotted to nitrocellulose BA83 (Whatman/Schleicher & Schuell, Dassel, Germany) for 6 hr at 600 mA at 4°C. Blots were blocked with 5% nonfat dried milk (Campina Melkunie, Zaltbommel, The Netherlands) in Tris-buffered saline (TBS) followed by an overnight incubation at 4°C with NCL-DYS1 (dilution 1:125; NovoCastra, Newcastle-upon-Tyne, UK) in TBS plus 0.05% Tween 20 to detect dystrophin. As secondary antibody the fluorescent IRDye 800CW goat anti-mouse IgG (dilution 1:5000, LI-COR, Lincoln, NE) was used. Blots were visualized and quantified with the Odyssey system and software (LI-COR).

Immunohistochemistry and dystrophin quantification

Sections (thickness, 8 μ m) were cut with a Shandon cryotome (Thermo Fisher Scientific) on Superfrost Plus slides (Thermo Fisher Scientific) along the entire length of the gastrocnemius with a minimal interval of 240 μ m between the sections. Slides were fixed for 5 min in ice-cold acetone and blocked with PBS–0.05% Tween–5% horse serum. Slides were incubated overnight with dystrophin diluted 1:50 (dystrophin [C-20] sc-7461; Santa Cruz Biotechnology, Heidelberg, Germany) and spectrin diluted 1:200 (anti-spectrin β -3 polyclonal antibody PA1-46007; Thermo Fisher Scientific) as primary antibodies. As secondary antibodies Alexa Fluor 488-conjugated donkey anti-goat IgG diluted 1:1000 (A11055; Invitrogen) for dystrophin and Alexa Fluor 594-conjugated donkey anti-rabbit IgG diluted 1:1000 (A21207; Invitrogen) for spectrin were used. Slides were mounted with VECTASHIELD HardSet mounting medium with 4',6-diamidino-2-phenylindole (DAPI) (H-1550; Vector Laboratories, Burlingame, CA). Images were made with a fluorescence microscope (Leica DM5500; Leica Microsystems, Rijswijk, The Netherlands) at $\times$ 20 magnification. Dystrophin levels were assessed with Leica MM Basic Offline software (Leica Microsystems) by calculating the average maximal intensity of 10 randomly placed rounds at the membranes minus the average of the average of 10 randomly placed rounds in the cytoplasm.

Biomarker analysis

Total RNA was purified with a NucleoSpin RNA II kit according to the manufacturer's instructions, including a DNase digestion (Macherey-Nagel, Düren, Germany). The integrity of the purified RNA was checked with an RNA 6000 Nano LabChip on the Agilent 2100 bioanalyzer (Agilent Technologies) according to the manufacturer's protocol.

One microgram of RNA was used for cDNA synthesis, using BioScript (GC biotech, Alphen aan den Rijn, The Netherlands) in 20 μ l at 70°C for 10 min and 42°C for 1 hr, with random hexamer primers (20 ng/ μ l). Gene expression

levels were determined for CD68, Lgals3 (lectin, galactoside binding, soluble, 3), biglycan, Lox, MyoD, myogenin, MRF4, and GAPDH (glyceraldehyde-3-phosphate dehydrogenase) by real-time qPCR, using SensiMix SYBR (GC biotech) and the Roche LightCycler 480 (Roche) (primer sequences on request), with a program consisting of 45 cycles of 95°C (10 sec), 60°C (30 sec), and 72°C (20 sec).

For microRNA (miRNA) analysis 1 μ g of unpurified RNA was used. Input RNA was reverse transcribed, using an miScript reverse transcription kit (Qiagen, Venlo, The Netherlands) according to the manufacturer's protocol. Two microliters of 10 times diluted cDNA was used as input for the real-time qPCR, using SensiMix SYBR (GC biotech) on the Roche LightCycler 480 (Roche), using a program consisting of 55 cycles of 95°C (10 sec), 57°C (30 sec), and 72°C (20 sec). Specific forward primers for miR-31 and 5S were used in combination with a universal reverse primer complementary to the adapter sequence of the RT-primer (primer sequences on request).

Calculations of relative expression were done with LinRegPCR quantitative PCR data analysis software, version 11.3 (Ruijter *et al.*, 2009). GAPDH, stably expressed across all conditions, was used to correct for differences in cDNA input for protein-coding transcripts and 5S was used to correct for differences in starting concentrations for miR-31.

Statistical analysis

Data are represented as means $\pm$ SD. Exon-skipping percentages, 23AON concentrations, and protein levels between AON and prednisolone plus AON groups were compared using an independent samples, two-tailed, Student *t* test in Excel 2003 (Microsoft Office Professional Edition 2003; Microsoft, Redmond, WA). Values of *p* less than 0.05 after correcting for multiple testing were considered significant.

Statistical significance between all four groups for dystrophin staining, plasma creatine kinase levels at the end of the experiment (day 64), and biomarker expression was assessed by one-way analysis of variance (ANOVA), followed by a Bonferroni correction for multiple testing in case of significance (*p* < 0.05) in SPSS 17.0.2 (SPSS, Chicago, IL).

To assess a possible treatment effect on the weight of mice over time a longitudinal analysis was performed in R (R Development Core Team, 2009), using the lme4 package (Bates and Maechler, 2010). A baseline corrected model was used, including fixed linear and quadratic time effects; the mouse effect was considered to be random.

Results

Prednisolone does not interfere with exon skipping in cultured cells and intramuscular 23AON injection

The effect of prednisolone on exon-skipping efficiency was first determined on cell cultures. Various doses of prednisolone were added to culture medium (0.2–2.25 μ g/ml). The highest dose did not induce cell death, but impaired differentiation was observed (data not shown), a known effect of corticosteroids (Schakman *et al.*, 2009). The dose of 0.75 μ g/ml was selected for further study, as it did not induce cell death, did not affect differentiation, and is comparable to the dose that is used in most patients (recommended dose, 0.75 mg/kg/day) (Mendell *et al.*, 1989; Khan, 1993; Bonifati *et al.*, 2000; Angelini, 2007).

Patient-derived cell cultures were pretreated for 10 days with prednisolone (0.75 $\mu\text{g}/\text{ml}$), or with saline as a control. Subsequently, cells were transfected with a 400 nM concentration of the appropriate AON. Skipping of the targeted exon was seen in all cells (Fig. 1) and no difference was seen between prednisolone- and saline-treated cells. Exon 51 skipping in cells with a deletion of exon 52 (53914.1) averaged 40% for both saline- and prednisolone-treated cells. For exon 50 skipping in cells with a deletion of exon 51–55 (DL589.2) the percentages were $\sim 70\%$, with relatively small variation (Fig. 1A). Similar exon-skipping levels were also found for other AON concentrations in the presence or absence of prednisolone (data not shown).

In vivo, the effect of systemic prednisolone treatment was first tested by local, intramuscular, injections with 23AON, a 2'-O-methyl phosphorothioate AON inducing exon 23 skipping [M23D(+2–18)] (Mann *et al.*, 2002). *mdx* mice were pretreated subcutaneously with saline or 1-mg/kg prednisolone for 4 weeks, starting at the age of 4 weeks (Payne *et al.*, 2006). This age was chosen because the major regeneration and degeneration cycles in *mdx* mice have been shown to take place at about this age (Tanabe *et al.*, 1986). The prednisolone dose is comparable to doses used by patients with DMD (Khan, 1993). At the age of 8 weeks, mice received two consecutive injections with 2.9 nmol of 23AON locally in the gastrocnemius muscles. Exon-skipping percentages were determined by primary PCR and bioanalyzer analysis (Spitali *et al.*, 2010). No significant

differences in exon-skipping levels were observed (Fig. 1B). Nested PCR analysis, the most commonly used method for determining exon skipping at present (Lu *et al.*, 2005; Denti *et al.*, 2008; Ivanova *et al.*, 2008; Yin *et al.*, 2008; Doran *et al.*, 2009; Heemskerk *et al.*, 2009), resulted in higher skipping levels of about 20% (data not shown). However, it has been shown that nested PCR gives an overestimation of absolute exon-skipping percentages (Spitali *et al.*, 2010).

Prednisolone does not affect exon skipping efficiency systemically in mdx mice

To investigate the effect of prednisolone on systemic treatment with 23AON, 5-week-old male *mdx* mice were treated for 8 weeks simultaneously with prednisolone (1 mg/kg/day via a subcutaneous slow-release pellet, shown to be an effective mode of delivery [Yao *et al.*, 2008; Guerron *et al.*, 2010]) or saline and 23AON (250 mg/kg, five times in week 1; and 100 mg/kg, two times in weeks 2 to 8, subcutaneously), or saline. During the treatment the weight of the mice was monitored. In contrast to the weight increase seen in humans, prednisolone-treated mice (both prednisolone alone and prednisolone and 23AON) weighed significantly less compared with saline- or 23AON alone-treated mice (Fig. 2A). This is in line with results described in the literature (Keeling *et al.*, 2007). In the absence of prednisolone, no difference in weight between 23AON- and saline-treated mice was observed. Plasma creatine kinase (CK) levels (a measure of muscle damage) did not differ significantly for the various groups after treatment (data not shown). Notably, levels were generally much lower than expected (up to 2000 U/liter in all mice, whereas, in general, levels up to 8000 U/liter are found in untreated *mdx* mice). This may have been due to the time between serum taking and measuring (1–4 weeks).

Average skipping levels were comparable for skeletal muscles and diaphragm and skipping levels did not differ between saline- and prednisolone-treated animals (Fig. 2B). In heart, exon-skipping levels were much lower, as described previously (Heemskerk *et al.*, 2009), but detectable in all samples. No skipping was observed without 23AON treatment for any of the muscles (data not shown).

Assessment of the concentrations of 23AON in the various tissues showed in prednisolone-treated mice a small, but significant decrease in 23AON concentration in the quadriceps and diaphragm (Fig. 2D). In the heart the levels were almost comparable to those found in skeletal muscle, without real difference between both treatment groups. The majority of the 23AON ends up in the liver and kidneys. Levels were similar in the liver for prednisolone-treated animals versus control animals, whereas an almost significant decrease in 23AON concentration was seen in the kidneys. Overall, 23AON levels in muscle and organs were slightly lower in the prednisolone-treated mice.

23AON-mediated expression of dystrophin protein is slightly increased in prednisolone-treated animals

Dystrophin protein expression was determined in two ways: by Western blot analysis and by immunofluorescence staining of cross-sections. Assessment of protein levels by Western blot (Fig. 3A and B) revealed restoration of expression in all 23AON-treated mice, albeit at low levels ($<5\%$ of wild-type control). Quantification indicated slightly elevated protein

FIG. 1. Effect of prednisolone on antisense oligonucleotide-mediated exon skipping *in vitro* and intramuscularly in the *mdx* mouse. Means are shown for each group. Error bars represent the standard deviation. **(A)** In two patient cell lines no effect on skipping percentages on addition of prednisolone was seen ($n=12$ per condition). For 53914.1 cells (deletion of exon 52) AONs against exon 51 were used, and for 589.2 cells (deletion of exons 51–55) AONs against exon 50 were used. **(B)** Prednisolone did not affect exon skipping after intramuscular injection of 23AON into the gastrocnemius of *mdx* mice. Per group, eight muscles were analyzed.

FIG. 2. Systemic treatment with prednisolone and/or 23AON. Shown is the effect on body weight of all treatments and antisense oligonucleotide-mediated exon skipping and 23AON biodistribution after cotreatment with prednisolone or saline. Per group, eight mice were analyzed. Means are shown for each group. Error bars represent the standard deviation. **(A)** Body weight was decreased in both prednisolone-treated groups compared with both saline- and 23AON alone-treated mice ($p < 0.01$). **(B)** RT-PCR analysis for the tibialis anterior. Wild-type product consists of 334 base pairs and exon 23 skipping results in a 122-base pair product. AON, antisense oligonucleotide; ctrls, controls; S, saline; P, prednisolone. **(C)** No difference in exon skip percentages between saline and prednisolone cotreatment with 23AONs was seen. Exon skip percentages were determined by DNA 1000 LabChip analysis on an Agilent 2100 bioanalyzer. **(D)** Biodistribution analysis showed a small decrease in 23AON uptake in the quadriceps and diaphragm, but not in the heart. ** $p < 0.01$ compared with 23AON alone-treated mice.

FIG. 3. Dystrophin expression detected by immunofluorescence staining and Western blot analysis. Per group, eight mice were analyzed. Means are shown for each group. Error bars represent the standard deviation. **(A)** Representative example of Western blot analysis (gastrocnemius muscle), showing low levels of dystrophin protein (*top*) in all 23AON-treated mice. No band was detected in control mice. Myosin (*bottom*) was used as loading control. **(B)** Quantification of dystrophin protein expression by Western blot showed a slight increase in protein levels in 23AON-treated mice, which was significant for the gastrocnemius muscle, but not for the diaphragm. * $p < 0.05$ compared with 23AON alone-treated mice. **(C)** Immunofluorescence staining with dystrophin antibody in the gastrocnemius muscle showed dystrophin expression above background levels in both 23AON-treated groups, but no difference between prednisolone- and saline-treated mice. ** $p < 0.01$ compared with saline-treated mice.

levels for mice treated with both prednisolone and 23AON compared with mice treated with 23AON alone; the difference was significant for the gastrocnemius. In the diaphragm the same trend was seen, but this increase was not significant (Fig. 3A and B). However, with these low dystrophin expression levels, differences may be more difficult to observe. Immunofluorescence staining showed dystrophin expression above background levels (saline/prednisolone alone-treated mice) for both 23AON-treated groups, but no difference was observed between saline- and prednisolone-treated animals (Fig. 3C). Untreated *mdx* mice did not express dystrophin.

Biomarkers

The expression levels of multiple mRNA transcripts have been shown to be changed in the *mdx* mouse. These can be used as biomarkers to assess the effect of therapeutic inter-

ventions ('t Hoen *et al.*, 2006). Expression levels for several immunological, fibrosis, and early and late regeneration markers for the tibialis anterior and diaphragm were assessed by quantitative PCR. The main changes in expression levels were seen in the tibialis anterior of 23AON- and/or prednisolone-treated mice (Fig. 4; and see Supplementary Table S1 online at www.liebertonline.com/hum). In the diaphragm the differences were relatively smaller. The immunological markers CD68 and Lgals3 are elevated in *mdx* mice and have been shown to fall after high levels of AAV-induced exon skipping ('t Hoen *et al.*, 2006). In our study, a significant decrease for both CD68 and Lgals3 was observed in the tibialis anterior of 23AON-treated mice (Fig. 4A and B). Prednisolone treatment did not induce a significant decrease for these immunological markers, although a trend was observed for both. Interestingly, for mice treated with both 23AONs and prednisolone, levels were higher than

FIG. 4. Expression of biomarker levels measured by quantitative PCR. Per group, eight mice were analyzed. Means are shown for each group, corrected for GAPDH or 5S expression. Values are expressed relatively to tibialis anterior levels of saline-treated mice. Error bars represent the standard deviation. Immunological markers CD68 (A) and Lgals3 (B), fibrotic markers biglycan (C) and Lox (D), early regeneration markers MyoD (E) and myogenin (F), late regeneration marker MRF4 (G) and miR-31 (H) were measured. miR-31 was determined only in the diaphragm (values expressed relatively to saline-treated mice) * $p < 0.05$ ** $p < 0.01$ compared with saline-treated mice.

those in mice treated with either compound. The fibrotic markers biglycan and Lox, known to be elevated in *mdx* mice (t Hoen *et al.*, 2006; Spurney *et al.*, 2008), were lower in the tibialis anterior of prednisolone-treated mice (only for Lox), 23AON-treated mice, as well as in mice receiving both treatments (Fig. 4C and D). Because of interindividual variations this difference was significant only for the group receiving both treatments compared with saline-treated mice for biglycan. To examine the effect of prednisolone and

23AON on regeneration, levels of the early regeneration markers MyoD and myogenin, which are elevated in *mdx* mice (Jin *et al.*, 2000), were measured. Both markers fell significantly after prednisolone and/or AON treatment (Fig. 4E and F). Furthermore, the late regeneration marker MRF4 has been shown to be inhibited by glucocorticoid treatment (te Pas *et al.*, 2000; Schakman *et al.*, 2009). Levels were highly variable in the tibialis anterior, but in the diaphragm a significant decrease compared with saline-treated mice was

seen for 23AON-treated mice with and without prednisolone (Fig. 4G). Another regeneration marker, the microRNA miR-31, showed a small decrease after both prednisolone and 23AON treatment, and a nearly significant decrease compared with control mice was seen after combinational treatment in the diaphragm (Fig. 4H). In conclusion, treatment with either prednisolone, 23AON, or a combination seems to normalize the levels of fibrotic and regenerative biomarkers to some extent in the tibialis anterior, whereas a smaller effect was observed in the more severely affected diaphragm.

Discussion

AON-mediated exon skipping as a potential therapy for DMD is being tested in placebo-controlled clinical trials and is likely to become clinically applicable in the near future. Most patients currently use corticosteroids, mainly prednisolone, to slow disease progression. Prednisolone has been shown to have a positive effect on muscle maintenance and quality. This could affect exon-skipping efficiency either positively or negatively. It has been noticed previously that uptake of AONs and exon-skipping efficiency are higher in dystrophic muscle than in wild-type muscle (Heemskerk *et al.*, 2010). This is thought to be caused by the leakiness of the dystrophic muscle membranes, which facilitates the entry of AONs into the muscle cells (Bremmer-Bout *et al.*, 2004; Heemskerk *et al.*, 2010). In fact, in mice containing only one utrophin allele in the absence of dystrophin (*mdx/utrn*^{+/-}), which are more severely affected, exon-skipping levels are higher than in the *mdx* mouse (Tanganyika-de Winter, C.L. *et al.*, unpublished observations). Therefore stabilization of the muscle fibers by prednisolone could have a negative effect on AON uptake and thereby decrease its efficiency. Conversely, improving the quality of the muscle could lead to more muscle fibers, increasing the total amount of dystrophin pre-mRNA, the target of AONs, and thereby increase the therapeutic potential of AONs. In this study the effect of prednisolone on AON uptake and biodistribution, exon-skipping levels, and dystrophin restoration was examined.

In two patient cell cultures and one healthy control cell culture no differences were seen in 2OMePS AON-induced exon skipping between prednisolone and saline cotreatment. Thus, the effect prednisolone has on muscle cells does not seem to influence skipping efficiency *in vitro*. The same appears to be true *in vivo*, where muscle cells are in their natural environment. After local injections of 23AON, skipping efficiency was the same between saline- and prednisolone-treated mice. The same holds for systemic 23AON treatment, where exon skipping percentages were similar between both treatment groups for skeletal muscle, diaphragm, and heart.

The 2OMePS dose used in this study is much higher than that used in clinical trials using the same chemistry (Goemans *et al.*, 2011) (200 vs. 6 mg/kg/week). However, for most drugs a correction factor applies when translating doses between small and larger animals, based on normalization to body surface area (see Guidance for Industry, <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078932.pdf>). When applying this correction factor, a dose of 16 mg/kg would be predicted for humans, which is on the same order of magnitude as the 6 mg/kg used in the trials. The slightly higher corrected dose for mice might be explained by a higher

clearance rate for 2OMePS AONs in mice and potential differences between pharmacokinetic and pharmacodynamic properties between exon 23- and exon 51-targeting AONs. In addition, regeneration is better in *mdx* mice than in human patients with DMD (Chamberlain *et al.*, 2007). This, together with the partial compensation for dystrophin-deficiency by utrophin, results in better muscle quality (fewer "leaky" fibers), leading to less uptake of the AON, which might also contribute to the higher corrected dose compared with clinical trials with 2OMePS AONs.

The exon-skipping levels *in vivo* after 2OMePS AON treatment (both locally and systemically) are relatively low. Vivo morpholinos (i.e., modified morpholinos, conjugated with a dendrimeric octaguanidine) have been shown to lead to much higher skip levels (Wu *et al.*, 2009, 2011). This may partly be due to differences in analysis method, primary versus nested PCR (Spitali *et al.*, 2010). In either case, at the moment the clinical relevance of these high levels is limited, as exon-skipping levels in the currently ongoing systemic trials are low (Cirak *et al.*, 2011; Goemans *et al.*, 2011). Higher exon skip efficiency would obviously be desired, but for now only nonconjugated AONs are being tested in clinical trials. Nevertheless, low levels of dystrophin protein have already led to histological and functional improvement in mice (van Putten and Aartsma-Rus, 2011; Goemans *et al.*, 2011), and the low exon-skipping levels in our study did result in dystrophin restoration, which was slightly increased in prednisolone-treated mice.

As seen in previous studies (Heemskerk *et al.*, 2009, 2010) the majority of the 23AON ends up in the liver and the kidneys after systemic treatment. A small decrease in 23AON concentration was seen in the quadriceps and diaphragm in prednisolone-treated mice compared with saline-treated mice, but this did not lead to a decrease in exon-skipping percentages. This might be explained by the localization of the AON within the tissue. The 23AON concentration is measured in whole muscle and therefore reflects AONs present both in the fibers (where exon skipping can be induced) and in the extracellular matrix and interstitial spaces (where no exon skipping can be induced). The lower levels observed in muscle may be due to less sequestration in the extracellular matrix caused by an improvement in muscle quality. Therefore, the higher levels in the AON-treated animals do not necessarily have to result in higher exon-skipping levels, because part may be sequestered in the extracellular matrix and interstitial spaces. This is supported by the finding that more dystrophin was expressed in prednisolone-treated mice, which might be another indication of a positive effect on muscle quality (more dystrophin pre-mRNA) by prednisolone, because the same percentage of skipping in more transcripts leads to higher protein production. In this study an AON with 2'-O-methyl phosphorothioate chemistry was used; however, it is anticipated that the results also hold for the other chemistry that is approaching use in large clinical trials (morpholino phosphorodiamidate AONs).

The best known effect of prednisolone is its suppressive effect on the immune system. However, no clear decrease in the immunological markers CD68 and Igals3 was seen in prednisolone-treated mice. By contrast, the levels of myogenic transcription factors MyoD and myogenin (regeneration markers) were decreased, although not significantly

everywhere, for all treated groups, suggesting that prednisolone treatment did have an effect on muscle. This concurs with previous findings that prednisolone treatment leads to a general reduction in proliferation, and MyoD and myogenin are downregulated in methylprednisolone-treated adrenalectomized rats (Almon *et al.*, 2007). Because AONs interact only with their target sequence, a general effect as observed for prednisolone is unlikely. In this case regeneration might be reduced because of reduction in muscle damage, inflammation, and fibrosis as a consequence of the dystrophin restoration. The less pronounced reduction in MRF-4 levels might be explained by the timing. MyoD and myogenin are elevated early in regeneration (Marotta *et al.*, 2007), peaking 72 hr after induction of regeneration (Jin *et al.*, 2000), whereas MRF-4 is increased in maturing myofibers (Marotta *et al.*, 2007). The combination of prednisolone and 23AON showed mixed effects. The absence of a decrease in immunological markers, as seen in 23AON-treated mice, is probably due to conflicting results in one or two mice, which abolish the small differences observed. Fibrotic and regeneration markers followed roughly the same pattern as prednisolone and/or 23AON treatment alone. miR-31 is a microRNA that, amongst other effects, targets the 3' untranslated region of the dystrophin mRNA, thereby repressing its translation and expression. It has been shown to be localized in regenerating myoblasts and is almost absent in wild-type muscle fibers, but is upregulated in *mdx* mice. Furthermore, repression of miR-31 led to an increase in dystrophin expression in AON-treated human DMD myoblasts (Cacchiarelli *et al.*, 2011). In all treated mice a trend was observed toward normalization, which seemed to be more pronounced after combinational treatment. The downregulation of miR-31 might be another explanation for the improved dystrophin levels after prednisolone treatment.

It is surprising that even the limited levels of dystrophin found in this short-term study resulted in improved muscle quality to some extent. However, the long-term presence of low amounts of dystrophin has been reported to result in beneficial effects before. The *mdx3cv* mouse model, which has approximately 5% of dystrophin since birth, performs significantly better in the grip strength test compared with *mdx* mice (Li *et al.*, 2008). Our own results in mice with low levels of dystrophin (*mdx-Xist^{Ahs}*) confirm these results; here, low levels of dystrophin (<15%) were sufficient to improve histology and muscle function and to normalize biomarkers (van Putten, M., *et al.*, manuscript submitted). Notably, in clinical trials low dystrophin levels after AON treatment appear to result in functional improvement (Goemans *et al.*, 2011).

In conclusion, this work shows that there is no negative effect of prednisolone and 23AON on each other's therapeutic outcome in any of the tests, suggesting that patients can continue using prednisolone during exon-skipping trials. Prednisolone might even have a positive effect on AON treatment.

Acknowledgments

The authors are grateful to Rick Vermue and Ruurd Verheul (Prosensa Therapeutics) for assistance with the hybridization–ligation assay, and to Maarten van Iterson (LUMC) for assistance with the statistical analysis. This work made use of the infrastructure of the Center for Medical

System Biology (CMSB) and the Center for Biomedical Genetics (CBG) in which the LUMC participates. LUMC is a partner in the FP6 TREAT-NMD network of excellence (LSHM-CT-2006–036825). This work is supported by grants from the Prinses Beatrix Fonds, The Netherlands (grant W-OR09-12) and the Dutch Duchenne Parent Project.

Author Disclosure Statement

Tatyana G. Karnaoukh, Ingrid G.M. Kolfschoten, Anne Vroon, and Judith C.T. van Deutekom report being employed by Prosensa Therapeutics. LUMC has patents on the exon-skipping applications. Hans Heemskerk, Gert-Jan B. van Ommen, Judith C.T. van Deutekom, and Annemieke Aartsma-Rus report being coinventors on some of these patents, and as such are entitled to a share of royalties.

References

- Aartsma-Rus, A., and van Ommen, G.J. (2007). Antisense-mediated exon skipping: A versatile tool with therapeutic and research applications. *RNA* 13, 1609–1624.
- Aartsma-Rus, A., Bremmer-Bout, M., Janson, A.A., *et al.* (2002). Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. *Neuromuscul. Disord.* 12(Suppl. 1), S71–S77.
- Aartsma-Rus, A., Janson, A.A., Kaman, W.E., *et al.* (2003). Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. *Hum. Mol. Genet.* 12, 907–914.
- Aartsma-Rus, A., Janson, A.A., Kaman, W.E., *et al.* (2004). Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. *Am. J. Hum. Genet.* 74, 83–92.
- Aartsma-Rus, A., van Vliet, L., Hirschi, M., *et al.* (2009). Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms. *Mol. Ther.* 17, 548–553.
- Acharyya, S., Villalta, S.A., Bakkar, N., *et al.* (2007). Interplay of IKK/NF- κ B signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. *J. Clin. Invest.* 117, 889–901.
- Alexakis, C., Partridge, T., and Bou-Gharios, G. (2007). Implication of the satellite cell in dystrophic muscle fibrosis: A self-perpetuating mechanism of collagen overproduction. *Am. J. Physiol. Cell Physiol.* 293, C661–C669.
- Almon, R.R., Dubois, D.C., and Jusko, W.J. (2007). A microarray analysis of the temporal response of liver to methylprednisolone: A comparative analysis of two dosing regimens. *Endocrinology* 148, 2209–2225.
- Anderson, L.V., and Davison, K. (1999). Multiplex Western blotting system for the analysis of muscular dystrophy proteins. *Am. J. Pathol.* 154, 1017–1022.
- Angelini, C. (2007). The role of corticosteroids in muscular dystrophy: A critical appraisal. *Muscle Nerve* 36, 424–435.
- Baltgalvis, K.A., Call, J.A., Nikas, J.B., and Lowe, D.A. (2009). Effects of prednisolone on skeletal muscle contractility in *mdx* mice. *Muscle Nerve* 40, 443–454.
- Bates, D., and Maechler, M. (2010). *lme4: Linear Mixed-Effects Models Using S4 Classes*. R package version 0.999375-35.
- Bauer, R., Straub, V., Blain, A., *et al.* (2009). Contrasting effects of steroids and angiotensin-converting-enzyme inhibitors in a mouse model of dystrophin-deficient cardiomyopathy. *Eur. J. Heart Fail.* 11, 463–471.
- Blake, D.J., Weir, A., Newey, S.E., and Davies, K.E. (2002). Function and genetics of dystrophin and dystrophin-related proteins in muscle. *Physiol. Rev.* 82, 291–329.

- Bonifati, M.D., Ruzza, G., Bonometto, P., *et al.* (2000). A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. *Muscle Nerve* 23, 1344–1347.
- Bremmer-Bout, M., Aartsma-Rus, A., de Meijer, E.J., *et al.* (2004). Targeted exon skipping in transgenic hDMD mice: A model for direct preclinical screening of human-specific antisense oligonucleotides. *Mol. Ther.* 10, 232–240.
- Cacchiarelli, D., Incitti, T., Martone, J., *et al.* (2011). miR-31 modulates dystrophin expression: New implications for Duchenne muscular dystrophy therapy. *EMBO Rep.* 12, 136–141.
- Chamberlain, J.S., Metzger, J., Reyes, M., *et al.* (2007). Dystrophin-deficient *mdx* mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. *FASEB J.* 21, 2195–2204.
- Chen, Y.W., Nagaraju, K., Bakay, M., *et al.* (2005). Early onset of inflammation and later involvement of TGF β in Duchenne muscular dystrophy. *Neurology* 65, 826–834.
- Cirak, S., Arechavala-Gomez, V., Guglieri, M., *et al.* (2011). Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: An open-label, phase 2, dose-escalation study. *Lancet* 378, 595–605.
- Denti, M.A., Incitti, T., Sthandier, O., *et al.* (2008). Long-term benefit of adeno-associated virus/antisense-mediated exon skipping in dystrophic mice. *Hum. Gene Ther.* 19, 601–608.
- Desguerre, I., Mayer, M., Leturcq, F., *et al.* (2009). Endomysial fibrosis in Duchenne muscular dystrophy: A marker of poor outcome associated with macrophage alternative activation. *J. Neuropathol. Exp. Neurol.* 68, 762–773.
- Doran, P., Wilton, S.D., Fletcher, S., and Ohlendieck, K. (2009). Proteomic profiling of antisense-induced exon skipping reveals reversal of pathobiochemical abnormalities in dystrophic *mdx* diaphragm. *Proteomics* 9, 671–685.
- Emery, A.E. (2002). The muscular dystrophies. *Lancet* 359, 687–695.
- Fisher, I., Abraham, D., Bouri, K., *et al.* (2005). Prednisolone-induced changes in dystrophic skeletal muscle. *FASEB J.* 19, 834–836.
- Gaud, A., Simon, J.M., Witzel, T., *et al.* (2004). Prednisone reduces muscle degeneration in dystrophin-deficient *Caenorhabditis elegans*. *Neuromuscul. Disord.* 14, 365–370.
- Goemans, N.M., Tulinus, M., van den Akker, J.T., *et al.* (2011). Systemic administration of PRO051 in Duchenne's muscular dystrophy. *N. Engl. J. Med.* 364, 1513–1522.
- Goyenvall, A., Babbs, A., Powell, D., *et al.* (2010). Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping. *Mol. Ther.* 18, 198–205.
- Guerron, A.D., Rawat, R., Sali, A., *et al.* (2010). Functional and molecular effects of arginine butyrate and prednisone on muscle and heart in the *mdx* mouse model of Duchenne muscular dystrophy. *PLoS One* 5, e11220.
- Hayden, M.S., and Ghosh, S. (2004). Signaling to NF- κ B. *Genes Dev.* 18, 2195–2224.
- Heemskerk, H., de Winter, C., van Kuik, P., *et al.* (2010). Pre-clinical PK and PD studies on 2'-O-methyl-phosphorothioate RNA antisense oligonucleotides in the *mdx* mouse model. *Mol. Ther.* 18, 1210–1217.
- Heemskerk, H.A., de Winter, C.L., de Kimpe, S.J., *et al.* (2009). *In vivo* comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. *J. Gene Med.* 11, 257–266.
- Hoffman, E.P., Brown, R.H., Jr., and Kunkel, L.M. (1987). Dystrophin: The protein product of the Duchenne muscular dystrophy locus. *Cell* 51, 919–928.
- Ivanova, G.D., Arzumanov, A., Abes, R., *et al.* (2008). Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in *mdx* mouse muscle. *Nucleic Acids Res.* 36, 6418–6428.
- Jin, Y., Murakami, N., Saito, Y., *et al.* (2000). Expression of MyoD and myogenin in dystrophic mice, *mdx* and *dy*, during regeneration. *Acta Neuropathol.* 99, 619–627.
- Jobling, A.I., and Augusteyn, R.C. (2002). What causes steroid cataracts? A review of steroid-induced posterior subcapsular cataracts. *Clin. Exp. Optom.* 85, 61–75.
- Keeling, R.M., Golumbek, P.T., Streif, E.M., and Connolly, A.M. (2007). Weekly oral prednisolone improves survival and strength in male *mdx* mice. *Muscle Nerve* 35, 43–48.
- Khan, M.A. (1993). Corticosteroid therapy in Duchenne muscular dystrophy. *J. Neurol. Sci.* 120, 8–14.
- Kinali, M., Arechavala-Gomez, V., Feng, L., *et al.* (2009). Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: A single-blind, placebo-controlled, dose-escalation, proof-of-concept study. *Lancet Neurol.* 8, 918–928.
- Koenig, M., Monaco, A.P., and Kunkel, L.M. (1988). The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. *Cell* 53, 219–228.
- Koenig, M., Beggs, A.H., Moyer, M., *et al.* (1989). The molecular basis for Duchenne versus Becker muscular dystrophy: Correlation of severity with type of deletion. *Am. J. Hum. Genet.* 45, 498–506.
- Li, D., Yue, Y., and Duan, D. (2008). Preservation of muscle force in *Mdx3cv* mice correlates with low-level expression of a near full-length dystrophin protein. *Am. J. Pathol.* 172, 1332–1341.
- Lo Cascio, V., Kanis, J.A., Beneton, M.N., *et al.* (1995). Acute effects of deflazacort and prednisone on rates of mineralization and bone formation. *Calcif. Tissue Int.* 56, 109–112.
- Lu, Q.L., Rabinowitz, A., Chen, Y.C., *et al.* (2005). Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. *Proc. Natl. Acad. Sci. U.S.A.* 102, 198–203.
- Mann, C.J., Honeyman, K., McClorey, G., *et al.* (2002). Improved antisense oligonucleotide induced exon skipping in the *mdx* mouse model of muscular dystrophy. *J. Gene Med.* 4, 644–654.
- Markham, L.W., Kinnett, K., Wong, B.L., *et al.* (2008). Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. *Neuromuscul. Disord.* 18, 365–370.
- Marotta, M., Sarria, Y., Ruiz-Roig, C., *et al.* (2007). Laser microdissection-based expression analysis of key genes involved in muscle regeneration in *mdx* mice. *Neuromuscul. Disord.* 17, 707–718.
- Mendell, J.R., Moxley, R.T., Griggs, R.C., *et al.* (1989). Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. *N. Engl. J. Med.* 320, 1592–1597.
- Merlini, L., Cicognani, A., Malaspina, E., *et al.* (2003). Early prednisone treatment in Duchenne muscular dystrophy. *Muscle Nerve* 27, 222–227.
- Mezzano, V., Cabrera, D., Vial, C., and Brandan, E. (2007). Constitutively activated dystrophic muscle fibroblasts show a paradoxical response to TGF- β and CTGF/CCN2. *J. Cell Commun. Signal.* 1, 205–217.
- Monaco, A.P., Bertelson, C.J., Liechti-Gallati, S., *et al.* (1988). An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. *Genomics* 2, 90–95.

- Payne, E.T., Yasuda, N., Bourgeois, J.M., *et al.* (2006). Nutritional therapy improves function and complements corticosteroid intervention in *mdx* mice. *Muscle Nerve* 33, 66–77.
- Porter, J.D., Khanna, S., Kaminski, H.J., *et al.* (2002). A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient *mdx* mice. *Hum. Mol. Genet.* 11, 263–272.
- R Development Core Team. (2009). *R: A Language and Environment for Statistical Computing*. (R Foundation for Statistical Computing, Vienna, Austria).
- Ruijter, J.M., Ramakers, C., Hoogaars, W.M., *et al.* (2009). Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data. *Nucleic Acids Res.* 37, e45.
- Schakman, O., Gilson, H., Kalista, S., and Thissen, J.P. (2009). Mechanisms of muscle atrophy induced by glucocorticoids. *Horm. Res.* 72(Suppl. 1), 36–41.
- Sicinski, P., Geng, Y., Ryder-Cook, A.S., *et al.* (1989). The molecular basis of muscular dystrophy in the *mdx* mouse: A point mutation. *Science* 244, 1578–1580.
- Silversides, C.K., Webb, G.D., Harris, V.A., and Biggar, D.W. (2003). Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy. *Am. J. Cardiol.* 91, 769–772.
- Spencer, M.J., and Tidball, J.G. (2001). Do immune cells promote the pathology of dystrophin-deficient myopathies? *Neuromuscul. Disord.* 11, 556–564.
- Spitali, P., Heemskerk, H., Vossen, R.H., *et al.* (2010). Accurate quantification of dystrophin mRNA and exon skipping levels in Duchenne muscular dystrophy. *Lab. Invest.* 90, 1396–1402.
- Spurney, C.F., Knoblach, S., Pistilli, E.E., *et al.* (2008). Dystrophin-deficient cardiomyopathy in mouse: Expression of Nox4 and Lox are associated with fibrosis and altered functional parameters in the heart. *Neuromuscul. Disord.* 18, 371–381.
- St-Pierre, S.J., Chakkalakal, J.V., Kolodziejczyk, S.M., *et al.* (2004). Glucocorticoid treatment alleviates dystrophic myofiber pathology by activation of the calcineurin/NF-AT pathway. *FASEB J.* 18, 1937–1939.
- Tanabe, Y., Esaki, K., and Nomura, T. (1986). Skeletal muscle pathology in X chromosome-linked muscular dystrophy (*mdx*) mouse. *Acta Neuropathol.* 69, 91–95.
- te Pas, M.F., de Jong, P.R., and Verburg, F.J. (2000). Glucocorticoid inhibition of C2C12 proliferation rate and differentiation capacity in relation to mRNA levels of the MRF gene family. *Mol. Biol. Rep.* 27, 87–98.
- 't Hoen, P.A., van der Wees, C.G., Aartsma-Rus, A., *et al.* (2006). Gene expression profiling to monitor therapeutic and adverse effects of antisense therapies for Duchenne muscular dystrophy. *Pharmacogenomics* 7, 281–297.
- Tidball, J.G. (2005). Inflammatory processes in muscle injury and repair. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 288, R345–R353.
- van Putten, M., and Aartsma-Rus, A. (2011). Opportunities and challenges for the development of antisense treatment in neuromuscular disorders. *Expert Opin. Biol. Ther.* 11, 1025–1037.
- van Deutekom, J.C., Janson, A.A., Ginjaar, I.B., *et al.* (2007). Local dystrophin restoration with antisense oligonucleotide PRO051. *N. Engl. J. Med.* 357, 2677–2686.
- Wu, B., Moulton, H.M., Iversen, P.L., *et al.* (2008). Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. *Proc. Natl. Acad. Sci. U.S.A.* 105, 14814–14819.
- Wu, B., Li, Y., Morcos, P.A., *et al.* (2009). Octa-guanidine morpholino restores dystrophin expression in cardiac and skeletal muscles and ameliorates pathology in dystrophic *mdx* mice. *Mol. Ther.* 17, 864–871.
- Wu, B., Benrashid, E., Lu, P., *et al.* (2011). Targeted skipping of human dystrophin exons in transgenic mouse model systemically for antisense drug development. *PLoS One* 6, e19906.
- Yao, W., Cheng, Z., Pham, A., *et al.* (2008). Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization. *Arthritis Rheum.* 58, 3485–3497.
- Yin, H., Moulton, H.M., Seow, Y., *et al.* (2008). Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. *Hum. Mol. Genet.* 17, 3909–3918.
- Yin, H., Moulton, H.M., Betts, C., *et al.* (2009). A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient *mdx* mice. *Hum. Mol. Genet.* 18, 4405–4414.
- Yu, R.Z., Baker, B., Chappell, A., *et al.* (2002). Development of an ultrasensitive noncompetitive hybridization–ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma. *Anal. Biochem.* 304, 19–25.

Address correspondence to:
Dr. Annemieke Aartsma-Rus
Department of Human Genetics
Leiden University Medical Center
P.O. Box 9600
2300 RC Leiden
The Netherlands

E-mail: a.m.rus@lumc.nl

Received for publication July 20, 2011;
accepted after revision October 17, 2011.

Published online: October 21, 2011.